F024 A Primer and Practical Approach to Cancer Checkpoint Inhibitors for the Dermatologist
DESCRIPTION
Novel cancer immunotherapies, specifically immune checkpoint inhibitors (CPIs), have recently emerged, redefining treatment paradigms in oncology. However, CPIs present significant complications, with pruritus and skin-related toxicities being among the most common adverse effects. These issues necessitate a new skill set for practitioners caring for cancer patients receiving this class of medication. This session aims to enhance dermatology practitioners' knowledge of the underlying science of cancer immunotherapies, common adverse events and skin-related toxicities, and current NCCN guidelines alongside other management strategies for CPI-induced adverse events.
LEARNING OBJECTIVES
Summarize the science of the novel cancer immunotherapies called checkpoint inhibitors and their mechanisms of actions.
Discuss the current FDA-approved checkpoint inhibitor therapies and their uses in dermatology along with associated adverse events and dermatology-related toxicities.
Apply the NCCN guideline recommendations for the management of checkpoint inhibitor-related skin toxicities.
SCHEDULE
9:00 AM
Introduction
Oliver J. Wisco, DO, FAAD
9:05 AM
Overview of FDA-Approved Checkpoint Inhibitors with a Focus on NCCN Guideline Skin Cancer Indications and Mechanism of Action for Each Class
Oliver J. Wisco, DO, FAAD
9:20 AM
Q&A with Dr. Wisco
Oliver J. Wisco, DO, FAAD
9:25 AM
Dermatologic CPI Neoadjuvant Use
Michael Tetzlaff, MD, PhD
9:40 AM
Q&A with Dr. Tetzlaff
Michael Tetzlaff, MD, PhD
9:45 AM
CPI Toxicity Incidence Overall and Correlation with Response with Concerns in Patients with Pre-Existing Skin Disease
Noah Io Hornick, MD, PhD, FAAD
10:00 AM
Q&A with Dr. Hornick
Noah Io Hornick, MD, PhD, FAAD
10:05 AM
Review of NCCN guidelines for Managing CPI ADRs and Dermatology-Related Toxicities
Jennifer N. Choi, MD, FAAD
10:20 AM
Q&A with Dr. Choi
Jennifer N. Choi, MD, FAAD
10:25 AM
Panel Discussion on Cutaneous Oncology Cases and Management of Checkpoint Inhibitor induced Dermatologic Toxicities
DIRECTOR
Oliver J. Wisco, DO, FAAD
SPEAKERS
Jennifer N. Choi, MD, FAAD
Noah Io Hornick, MD, PhD, FAAD
Michael Tetzlaff, MD, PhD
DISCLOSURES
Jennifer N. Choi, MD, FAAD
CeraVe/Valeante – Independent Contractor(Fees); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); PraHealth Sciences – Advisory Board(Fees); Pyxis Oncology – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);
Noah Io Hornick, MD, PhD, FAAD
Shook Hardy & Bacon – Consultant (1099 relationship)(Fees); Therakos, Inc. – Data Safety Monitoring Board(Fees);
Michael Tetzlaff, MD, PhD
Merck – Other(Fees); Philogen S.p.A. – Advisory Board(Fees); Regeneron – Advisory Board(Honoraria);
Oliver J. Wisco, DO, FAAD
Castle Biosciences – Investigator(Fees); Regeneron – Consultant (1099 relationship)(Fees), Investigator(Fees);